{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T17:11:00Z","timestamp":1725297060385},"reference-count":35,"publisher":"American Society of Tropical Medicine and Hygiene","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"abstract":"<jats:p>West Nile virus (WNV) causes serious neurologic disease, but no licensed vaccines are available to prevent this disease in humans. We have developed RepliVAX WN, a single-cycle flavivirus with an expected safety profile superior to other types of live-attenuated viral vaccines. In this report we describe studies examining RepliVAX WN safety, potency, and efficacy in a non-human primate model of WNV infection. A single immunization of four rhesus macaques with RepliVAX WN was safe and elicited detectable neutralizing antibody titers and IgM and IgG responses, and IgG titers were increased in two animals that received a second immunization. After challenge with WNV, three of four immunized animals were completely protected from viremia, and the remaining animal showed minimal viremia on one day. In contrast, the unvaccinated animal developed viremia that lasted six days. These results demonstrate the efficacy and safety of RepliVAX WN in this primate model of WNV infection.<\/jats:p>","DOI":"10.4269\/ajtmh.2010.09-0310","type":"journal-article","created":{"date-parts":[[2010,6,2]],"date-time":"2010-06-02T19:04:52Z","timestamp":1275505492000},"page":"1160-1167","source":"Crossref","is-referenced-by-count":28,"title":["Evaluation of RepliVAX WN, a Single-Cycle Flavivirus Vaccine, in a Non-Human Primate Model of West Nile Virus Infection"],"prefix":"10.4269","volume":"82","author":[{"given":"Douglas G.","family":"Widman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis D.","family":"Giavedoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vida L.","family":"Hodara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa de la","family":"Garza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Montalbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia P.","family":"Travassos Da Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"Tesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean L.","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Carrion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Bourne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter W.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2795","reference":[{"year":"2009","series-title":"West Nile Virus - Statistics, Surveillance, and Control - Case Count 2008","author":"Centers for Disease Control and Prevention","key":"R1"},{"key":"R2","series-title":"J Virol","first-page":"4040","article-title":"West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays","volume":"75","author":"Davis","year":"2001"},{"key":"R3","series-title":"Equine vaccine for West Nile virus. Dev Biol (Basel)","first-page":"221","volume":"114","author":"Ng","year":"2003"},{"key":"R4","series-title":"Arch Virol Suppl","first-page":"221","article-title":"Recombinant canarypoxvirus vaccine carrying the prM\/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge","author":"Minke","year":"2004"},{"key":"R5","series-title":"J Infect Dis","first-page":"1732","article-title":"A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial","volume":"196","author":"Martin","year":"2007"},{"key":"R6","series-title":"Proc Natl Acad Sci USA","first-page":"6694","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006"},{"key":"R7","series-title":"Vaccine","first-page":"2913","article-title":"Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis","volume":"25","author":"Watts","year":"2007"},{"key":"R8","series-title":"J Virol","first-page":"1672","article-title":"Proper maturation of the Japanese encephalitis virus envelope glycoprotein requires cosynthesis with the premembrane protein","volume":"67","author":"Konishi","year":"1993"},{"key":"R9","series-title":"Virology","first-page":"294","article-title":"Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection","volume":"180","author":"Mason","year":"1991"},{"key":"R10","series-title":"Virology","first-page":"714","article-title":"Mice immunized with a subviral particle containing the Japanese encephalitis virus prM\/M and E proteins are protected from lethal JEV infection","volume":"188","author":"Konishi","year":"1992"},{"key":"R11","series-title":"J Infect Dis","first-page":"2104","article-title":"Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells","volume":"190","author":"Qiao","year":"2004"},{"key":"R12","series-title":"J Immunol","first-page":"6756","article-title":"A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms","volume":"163","author":"Aberle","year":"1999"},{"key":"R13","series-title":"Vaccine","first-page":"1133","article-title":"A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice","volume":"18","author":"Konishi","year":"2000"},{"key":"R14","series-title":"Virology","first-page":"432","article-title":"Production and characterization of vaccines based on flaviviruses defective in replication","volume":"351","author":"Mason","year":"2006"},{"key":"R15","series-title":"Vaccine","first-page":"2762","article-title":"Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system","volume":"26","author":"Widman","year":"2008"},{"key":"R16","series-title":"Vaccine","first-page":"5550","article-title":"RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters","volume":"27","author":"Widman","year":"2009"},{"key":"R17","series-title":"N Engl J Med","first-page":"608","article-title":"Protection against Japanese encephalitis by inactivated vaccines","volume":"319","author":"Hoke","year":"1988"},{"key":"R18","series-title":"Vaccine","first-page":"919","author":"Halstead","year":"2004"},{"key":"R19","series-title":"Wkly Epidemiol Rec","first-page":"337","article-title":"Japanese encephalitis vaccines","volume":"73","author":"World Health Organization","year":"1998"},{"key":"R20","series-title":"Emerg Infect Dis","first-page":"714","article-title":"West Nile virus infection in the golden hamster (Mesocricetus auratus): a model for West Nile encephalitis","volume":"7","author":"Xiao","year":"2001"},{"key":"R21","series-title":"J Virol","first-page":"9100","article-title":"Early production of type i interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production","volume":"81","author":"Bourne","year":"2007"},{"key":"R22","series-title":"J Virol","first-page":"1742","article-title":"Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys","volume":"74","author":"Monath","year":"2000"},{"key":"R23","series-title":"Am J Trop Med Hyg","first-page":"561","article-title":"Techniques for hemagglutination and hemagglutination-inhibition with arthropod-borne viruses","volume":"7","author":"Clarke","year":"1958"},{"key":"R24","series-title":"J Hyg (Lond)","first-page":"329","article-title":"A simplified method for the detection of rubella-specific IgM employing sucrose density fractionation and 2-mercaptoethanol","volume":"73","author":"Caul","year":"1974"},{"key":"R25","series-title":"J Infect Dis","first-page":"669","article-title":"Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection","volume":"189","author":"Ratterree","year":"2004"},{"key":"R26","series-title":"J Virol","first-page":"12497","article-title":"ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy","volume":"78","author":"Arroyo","year":"2004"},{"key":"R27","series-title":"Vaccine","first-page":"6392","article-title":"Chimeric West Nile\/dengue virus vaccine candidate: preclinical evaluation in mice, geese and monkeys for safety and immunogenicity","volume":"24","author":"Pletnev","year":"2006"},{"key":"R28","series-title":"Vaccine","first-page":"2020","article-title":"The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus","volume":"26","author":"Shrestha","year":"2008"},{"key":"R29","series-title":"Vaccine","first-page":"3722","article-title":"Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVax-JE experimental vaccine","volume":"22","author":"Beasley","year":"2004"},{"key":"R30","series-title":"J Virol","first-page":"8312","article-title":"Role of CD8+ T cells in control of West Nile virus infection","volume":"78","author":"Shrestha","year":"2004"},{"key":"R31","series-title":"J Virol","first-page":"3076","article-title":"Neutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus protein","volume":"72","author":"Kreil","year":"1998"},{"issue":"(Suppl 1)","key":"R32","series-title":"Vaccine","first-page":"S41","article-title":"History of TBE vaccines","volume":"21","author":"Barrett","year":"2003"},{"key":"R33","series-title":"Am J Trop Med Hyg","first-page":"533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial","volume":"66","author":"Monath","year":"2002"},{"key":"R34","series-title":"Virology","first-page":"190","article-title":"Molecularly engineered live-attenuated chimeric West Nile\/dengue virus vaccines protect rhesus monkeys from West Nile virus","volume":"314","author":"Pletnev","year":"2003"},{"key":"R35","series-title":"J Virol","first-page":"13640","article-title":"Differential activation of human monocyte-derived and plasmacytoid dendritic cells by West Nile virus generated in different host cells","volume":"81","author":"Silva","year":"2007"}],"container-title":["The American Society of Tropical Medicine and Hygiene"],"original-title":[],"link":[{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/82\/6\/article-p1160.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/82\/6\/article-p1160.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.ajtmh.org\/downloadpdf\/journals\/tpmd\/82\/6\/article-p1160.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T15:59:05Z","timestamp":1725292745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajtmh.org\/view\/journals\/tpmd\/82\/6\/article-p1160.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":35,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.4269\/ajtmh.2010.09-0310","relation":{},"ISSN":["0002-9637","1476-1645"],"issn-type":[{"type":"print","value":"0002-9637"},{"type":"electronic","value":"1476-1645"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}